CliniWorks today announced a strategic alliance between and Pfizer Inc. (NYSE:PFE) to jointly advance the parties’ respective capabilities in working with healthcare provider organizations to identify and close clinical or quality gaps to improve population health. The two companies are partnering to develop a population health management platform solution that leverages CliniWorks’ technologies in disparate data aggregation and Natural Language Processing (which interprets free text information) of de-identified healthcare data and Pfizer’s scientific, clinical and disease expertise. Pfizer Inc. (NYSE:PFE) stock performance was 0.13% in last session and finished the day at $30.49. Traded volume was 17.55million shares in the last session and the average volume of the stock remained 29.17million shares. The beta of the stock remained 0.67. Pfizer Inc. (NYSE:PFE) insider ownership is 0.10%.

Arena Pharmaceuticals (NASDAQ:ARNA) shares plunged Monday on news that its chief executive Jack Lief sold nearly 40 percent of his holdings in the company. Lief sold 223,525 shares on July 1 at $5.85 per share. The transaction was an “automatic sell” apparently triggered by a declining share price. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) dropped -9.42 percent to $5.29 Monday on volume of 12.57million shares. The intra-day range of the stock was $5.22 to $5.69. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has a market capitalization of $1.16billion.

Biotechs Gilead Sciences (NASDAQ:GILD) and Anika Therapeutics (NASDAQ:ANIK) are among just a few stocks in the Spotlight screen that are still hovering near buy points. Gilead Sciences, Inc. (NASDAQ:GILD)’s stock on July 07, 2014 reported a decrease of -0.78% to the closing price of $87.21. Its fifty two weeks range is $52.27 -$88.40. The total market capitalization recorded $133.93billion. The overall volume in the last trading session was 11.46million shares. In its share capital, GILD has 1.54billion outstanding shares.

MannKind Corp (NASDAQ:MNKD) CFO Matthew J. Pfeffer unloaded 20,000 shares of the stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $10.44, for a total value of $208,800.00. Following the sale, the chief financial officer now directly owns 126,784 shares in the company, valued at approximately $1,323,625. On Monday, shares of MannKind Corporation (NASDAQ:MNKD) dropped -0.90% to close the day at $9.91. Company monthly performance is recorded as -1.29%. MannKind Corporation (NASDAQ:MNKD) quarterly revenue growth is 44.25%.